Agios Pharmaceuticals Files Q3 2024 10-Q

TL;DR

Agios Q3 10-Q is in. Check financials for latest performance.

AI Summary

Agios Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine months of 2024. Specific financial figures and operational details for this period are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Agios Pharmaceuticals, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Agios is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 20240930 — Reporting Period End Date (Indicates the end of the fiscal quarter for which results are reported.)
• 20241031 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• AGIOS PHARMACEUTICALS, INC. (company) — Filer of the 10-Q
• 20240930 (date) — End of the reporting period
• 20241031 (date) — Filing date
• 0001439222 (company) — CIK number for Agios Pharmaceuticals

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, Par Value $0.001 per share AGIO Nasdaq Global Select Mar

Filing Documents

• agio-20240930.htm (10-Q) — 1376KB
• exhibit31-1x09x30x24.htm (EX-31.1) — 9KB
• exhibit31-2x09x30x24.htm (EX-31.2) — 9KB
• exhibit32-1x09x30x24.htm (EX-32.1) — 5KB
• exhibit32-2x09x30x24.htm (EX-32.2) — 5KB
• 0001439222-24-000138.txt ( ) — 6344KB
• agio-20240930.xsd (EX-101.SCH) — 43KB
• agio-20240930_cal.xml (EX-101.CAL) — 74KB
• agio-20240930_def.xml (EX-101.DEF) — 165KB
• agio-20240930_lab.xml (EX-101.LAB) — 560KB
• agio-20240930_pre.xml (EX-101.PRE) — 388KB
• agio-20240930_htm.xml (XML) — 824KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 202 3 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Inco m e ( Loss ) for the Three and Nine Months Ended September 30 , 2024 and 2023 3 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30 , 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30 , 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION 32 Item 1A.

Risk Factors

Risk Factors 32 Item 5. Other Information 63 Item 6. Exhibits 65

Signatures

Signatures 66 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) AGIOS PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share data) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 253,730 $ 88,205 Marketable securities 751,027 688,723 Accounts receivable, net 3,118 2,810 Inventory 26,429 19,076 Prepaid expenses and other current assets 39,885 35,021 Total current assets 1,074,189 833,835 Marketable securities 655,889 29,435 Operating lease assets 45,841 54,409 Property and equipment, net 11,819 15,382 Other non-current assets 4,056 4,057 Total assets $ 1,791,794 $ 937,118 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 17,143 $ 9,780 Accrued expenses 33,307 43,167 Income taxes payable 52,682 — Operating lease liabilities 16,319 15,008 Total current liabilities 119,451 67,955 Operating lease liabilities, net of current portion 44,515 56,988 Other non-current liabilities 1,156 1,156 Total liabilities 165,122 126,099 Stockholders' equity: Preferred stock, $ 0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value; 125,000,000 shares authorized; 73,237,954 shares issued and 57,021,543 shares outstanding at September 30, 2024, and 72,161,489 shares issued and 55,945,078 shares outstanding at December 31, 2023 73 72 Additional paid-in capital 2,478,066 2,436,523 Accumulated other comprehensive income (loss) 3,420 ( 441 ) Treasury stock, at cost ( 16,216,411 shares at September 30, 2024 and December 31, 2023) ( 802,486 ) ( 802,486 ) Accumulated deficit ( 52,401 ) ( 822,649 ) Total stockholders' equity 1,626,672 811,019 Total liabilities and stockholders' equity $ 1,791,794 $ 937,118 See accompanying Notes to Condensed Consolidated Financial Statements. 1 Table of Contents AGIOS PHARMACEUTICALS, INC. Condensed Consol

View Full Filing

View this 10-Q filing on SEC EDGAR